Relmada Therapeutics(RLMD) - 2025 Q4 - Annual Results

Exhibit 99.1 Relmada Therapeutics Reports Fourth Quarter and Full Year 2025 Results and Provides Business Update CORAL GABLES, FL – March 19, 2026 (Globe Newswire) – Relmada Therapeutics, Inc. (Nasdaq: RLMD, "Relmada" or the "Company"), a clinical-stage biotechnology company advancing innovative therapies for oncology and central nervous system disorders, today reported audited financial results for the fourth quarter and full year ended December 31, 2025 and provided a corporate update highlighting signifi ...